Inspira Technologies OXY BHN Ltd. announced that it has received U.S. Patent approval for its ART500 core technology. This patent is a significant development for the company's efforts to penetrate the estimated $20 billion market for advanced respiratory support. The newly approved patent offers protection until 2043, covering key aspects of the ART500's functionality, design, and clinical applications. This advancement strengthens Inspira's intellectual property portfolio and provides a competitive edge in the field of advanced extracorporeal life support.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inspira Technologies OXY BHN Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-079586), on August 22, 2025, and is solely responsible for the information contained therein.